Fill in this information to identify the case:				
Debtor	Eiger BioPharmaceuticals, Inc			
United States Ba	nkruptcy Court for the: Northern	District of(State)		
Case number	24-80040	_		

Official Form 410 Proof of Claim

04/22

248004024071700000000008

Read the instructions before filling out this form. This form is for making a claim for payment in a bankruptcy case. Do not use this form to make a request for payment of an administrative expense. Make such a request according to 11 U.S.C. § 503.

Filers must leave out or redact information that is entitled to privacy on this form or on any attached documents. Attach redacted copies or any documents that support the claim, such as promissory notes, purchase orders, invoices, itemized statements of running accounts, contracts, judgments, mortgages, and security agreements. Do not send original documents; they may be destroyed after scanning. If the documents are not available, explain in an attachment.

A person who files a fraudulent claim could be fined up to \$500,000, imprisoned for up to 5 years, or both. 18 U.S.C. §§ 152, 157, and 3571.

Fill in all the information about the claim as of the date the case was filed. That date is on the notice of bankruptcy (Form 309) that you received.

Pa	art 1: Identify the Clair	n			
1.	Who is the current creditor?	Stanford University Name of the current creditor (the person or entity to be paid for this claim) Other names the creditor used with the debtor EIG-LMD-002, Proj Code 157-2			
2.	Has this claim been acquired from someone else?	No Yes. From whom?			
3.	Where should notices and payments to the creditor be sent? Where should notices to the creditor be sent? See summary page See summary page Federal Rule of Bankruptcy Procedure (FRBP) 2002(g) Contact phone 6507250086 Contact phone Contact email See summary page		Where should payments to the creditor be sent? (if different) Contact phone Contact email		
4.	Does this claim amend one already filed?	Uniform claim identifier for electronic payments in chapter 13 (if you us			
5.	Do you know if anyone else has filed a proof of claim for this claim?	□ No ☑ Yes. Who made the earlier filing? Myself			

3.	o you have any number	No No
	you use to identify the debtor?	Yes. Last 4 digits of the debtor's account or any number you use to identify the debtor: VAGWT
7.	How much is the claim?	\$ 19,860.58 Does this amount include interest or other charges?
		No
		Yes. Attach statement itemizing interest, fees, expenses, or other charges required by Bankruptcy Rule 3001(c)(2)(A).
3.	What is the basis of the claim?	Examples: Goods sold, money loaned, lease, services performed, personal injury or wrongful death, or credit card.
		Attach redacted copies of any documents supporting the claim required by Bankruptcy Rule 3001(c).
		Limit disclosing information that is entitled to privacy, such as health care information.
		Services performed
9.	Is all or part of the claim	No
	secured?	Yes. The claim is secured by a lien on property.
		Nature or property:
		Real estate: If the claim is secured by the debtor's principle residence, file a <i>Mortgage Proof of Claim Attachment</i> (Official Form 410-A) with this <i>Proof of Claim</i> .
		Motor vehicle
		Other. Describe:
		Basis for perfection: Attach redacted copies of documents, if any, that show evidence of perfection of a security interest (for example, a mortgage, lien, certificate of title, financing statement, or other document that shows the lien has been filed or recorded.)
		Value of property: \$
		Amount of the claim that is secured: \$
		Amount of the claim that is unsecured: \$(The sum of the secured and unsecured amount should match the amount in line 7.
		Amount necessary to cure any default as of the date of the petition: \$
		Annual Interest Rate (when case was filed)%
		Fixed
		Variable
10.	Is this claim based on a	No
	lease?	Yes. Amount necessary to cure any default as of the date of the petition.
11.	Is this claim subject to a	No
	right of setoff?	Yes. Identify the property:

12. Is all or part of the claim entitled to priority under	No No		
11 U.S.C. § 507(a)?	Yes. Chec	k all that apply:	Amount entitled to priority
A claim may be partly priority and partly		estic support obligations (including alimony and child support) under S.C. \S 507(a)(1)(A) or (a)(1)(B).	\$
nonpriority. For example, in some categories, the law limits the amount		\$3,350* of deposits toward purchase, lease, or rental of property vices for personal, family, or household use. 11 U.S.C. § 507(a)(7).	\$
entitled to priority.	days	es, salaries, or commissions (up to \$15,150*) earned within 180 before the bankruptcy petition is filed or the debtor's business ends, lever is earlier. 11 U.S.C. § 507(a)(4).	\$
	Taxes	s or penalties owed to governmental units. 11 U.S.C. § 507(a)(8).	\$
	Contr	ibutions to an employee benefit plan. 11 U.S.C. § 507(a)(5).	\$
	Other	. Specify subsection of 11 U.S.C. § 507(a)() that applies.	\$
	* Amounts	are subject to adjustment on 4/01/25 and every 3 years after that for cases begun	on or after the date of adjustment.
13. Is all or part of the claim entitled to administrative priority pursuant to 11 U.S.C. 503(b)(9)?	Yes. Indic days befo	ate the amount of your claim arising from the value of any goods rece re the date of commencement of the above case, in which the goods ry course of such Debtor's business. Attach documentation supportin	have been sold to the Debtor in
Part 3: Sign Below			
The person completing this proof of claim must sign and date it. FRBP 9011(b). If you file this claim electronically, FRBP 5005(a)(2) authorizes courts to establish local rules specifying what a signature is. A person who files a fraudulent claim could be fined up to \$500,000, imprisoned for up to 5 years, or both. 18 U.S.C. §§ 152, 157, and 3571.	□ I am the trus □ I am a guara I understand that the amount of the I have examined to I declare under per Executed on date	litor. ditor's attorney or authorized agent. tee, or the debtor, or their authorized agent. Bankruptcy Rule 3004. ntor, surety, endorser, or other codebtor. Bankruptcy Rule 3005. an authorized signature on this <i>Proof of Claim</i> serves as an acknowledge claim, the creditor gave the debtor credit for any payments received to he information in this <i>Proof of Claim</i> and have reasonable belief that the enalty of perjury that the foregoing is true and correct. $\frac{07/17/2024}{MM / DD / YYYY}$	ward the debt. e information is true and correct.
	Contact phone	Email	

Verita (KCC) ePOC Electronic Claim Filing Summary

For phone assistance: Domestic (888) 733-1544 | International (310) 751-2638

Debtor:		
24-80040 - Eiger BioPharmaceuticals, Inc		
District:		
Northern District of Texas, Dallas Division		
Creditor:	Has Supporting Do	cumentation:
Stanford University	Yes, suppor	ting documentation successfully uploaded
Stanford University	Related Document	Statement:
485 Broadway, University Hall, Third Floor		
	Has Related Claim:	
Redwood City, California, 94063-3136	Yes	
United States	Related Claim Filed	і Ву:
Phone:	Myself	
6507250086	Filing Party:	
Phone 2:	Authorized a	igent
Fax:		
Email:		
RFCS-RECEIVABLES@LISTS.STANFORD.EDU		
Other Names Used with Debtor:	Amends Claim:	
EIG-LMD-002, Proj Code 157-2	Yes, 07/17/2024	
	Acquired Claim:	
	No	
Basis of Claim:	Last 4 Digits:	Uniform Claim Identifier:
Services performed	Yes - VAGWT	
Total Amount of Claim:	Includes Interest o	r Charges:
19,860.58	No	
Has Priority Claim:	Priority Under:	
No		
Has Secured Claim:	Nature of Secured	Amount:
No	Value of Property:	
Amount of 503(b)(9):	Annual Interest Ra	te:
No		
Based on Lease:	Arrearage Amount	
No	Basis for Perfectio	n:
Subject to Right of Setoff:	Amount Unsecured	1:
No		
Submitted By:		
Natalia Antanavage on 17-Jul-2024 6:11:59 p.m. Easter	rn Time	
Title:		
Director of SRM		
Company:		
Stanford University		

Office of Research Administration

Sponsored Receivables Management

Tax ID Number 94-1156365

INVOICE

	Award	Number:	VAGWT	
то:	Date	04/08/2024	Invoice Number:	58074-2282503-20
EIGER BIOPHARMACEUTICAL		Billing Period:	02/01/24 - 04/08/24	
C/O BIORASI LLC			Sponsor Ref No:	EIG-LMD-002,Proj Code 157-2
18851 NE 29TH AVE #800 AVENTURA, FL 33180 US		Payment Terms :	30 NET	
AVENIONA, FE 55100 (

SUBMIT PAYMENT WITH INVOICE NO. TO: Stanford University PO BOX 884253 LOS ANGELES, CA 90088-4253

PI: Kwo, Paul Y.

Award Title: A Phase 3, Randomized, Open-Label, Parallel Arm Study to Evaluate the Efficacy and Safety of 180 mcg Peginterferon Lambda-1a (Lambda) Subcutaneous Injection for 48 Weeks in Patients with Chronic Hepatitis Delta Virus (HDV) Infection (LIMT-2

Billing Item	Amount
205317: Other Study Related	2,983.00
Fees	

CURRENT AMOUNT DUE: \$2,983.00

Please remit "Current Amount Due" with this invoice to prevent further collection efforts. If payment has been made, please disregard this message. Please call (650) 725-0086 or email rfcs-receivables@list.stanford.edu for questions.

I hereby affirm that the above bill is correct and just and that payment thereof has not been received THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY

Natalia

Digitally signed by Natalia Antanavage DN: cn=Natalia Antanavage, o=ORA, ou=SRM

Director of SRM



SPO#:275134, Award#: VAGWT, Principal Investigator: Kwo, Paul Y, Sponsor: Eiger BioPharmaceuticals, Inc.

Fee	Date	Amount
Study Closeout \$1983	28-MAR-2024	\$1,983.00
Document Archiving (Paid at Study Close Out) \$1000	28-MAR-2024	\$1,000.00
Total		\$2,983.00

Office of Research Administration

Sponsored Receivables Management

Tax ID Number 94-1156365

INVOICE

		Award	Number:	VAGWT	
	то:	Date	01/31/2024	Invoice Number:	58074-2268447-11
EIGER BIOPHARMACEUTICAL		Billing Period:	01/26/24 - 01/31/24		
	C/O BIORASI LLC			Sponsor Ref No:	EIG-LMD-002,Proj Code 157-2
18851 NE 29TH AVE #800 AVENTURA, FL 33180 US		Payment Terms :	30 NET		
	C/O BIORASI LLC 18851 NE 29TH AVE #8	CAL 00		Billing Period: Sponsor Ref No:	01/26/24 - 01/31/24 EIG-LMD-002,Proj Code 157-2

SUBMIT PAYMENT WITH INVOICE NO. TO: Stanford University PO BOX 884253 LOS ANGELES, CA 90088-4253

PI: Kwo, Paul Y.

Award Title: A Phase 3, Randomized, Open-Label, Parallel Arm Study to Evaluate the Efficacy and Safety of 180 mcg Peginterferon Lambda-1a (Lambda) Subcutaneous Injection for 48 Weeks in Patients with Chronic Hepatitis Delta Virus (HDV) Infection (LIMT-2

Billing I	tem	Amount
201911: Fees	Other Study Related	1,576.74

CURRENT AMOUNT DUE: \$1,576.74

Please remit "Current Amount Due" with this invoice to prevent further collection efforts. If payment has been made, please disregard this message. Please call (650) 725-0086 or email rfcs-receivables@list.stanford.edu for questions.

I hereby affirm that the above bill is correct and just and that payment thereof has not been received THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY

Natalia

Digitally signed by Natalia Antanavage DN: cn=Natalia Antanavage, o=ORA, ou=SRM

Director of SRM



Fee	Date	Amount
9019-2001 - TFTs = thyroid function tests (Local lab)	24-FEB-2023	\$218.42
9019-2001 - AFB = alfa fetoprotein (Local lab)	24-FEB-2023	\$48.15
9019-2001 - coagulation parameters (Local lab)	24-FEB-2023	\$60.02
9019-2001 - HCV RNA Viral load, HCV serology, HDV Serology (*4&5), HDV RNA Viral Load (*4&5), HIV RNA Viral Load, HIV Serology (Through local laboratory only for SV1, if no historical data is available)	24-FEB-2023	\$556.86
9019-2001 - Clinical Laboratory Test (Hematology Local lab)	24-FEB-2023	\$46.54
9019-2001 - Clinical Laboratory Test (Chemistry Local lab)	24-FEB-2023	\$120.38
9019-2001 - Urinalysis test (Local lab)	24-FEB-2023	\$45.39
9019-2001 - PT = prothrombin time (Local lab)	24-FEB-2023	\$43.66
9019-2001 - Ophthalmologist exam	19-MAY-2023	\$162.00
9019-2001 - Fibroscan	19-MAY-2023	\$137.66
9019-2001 - Fibroscan	13-SEP-2023	\$137.66
Total		\$1,576.74

Office of Research Administration Sponsored Receivables Management

Tax ID Number 94-1156365

INVOICE

	Award	Number:	VAGWT	
то:	Date	07/29/2023	Invoice Number:	58074-2236872-3
EIGER BIOPHARMACEUTICAL		Billing Period:	06/30/23 - 07/29/23	
C/O BIORASI LLC			Sponsor Ref No:	EIG-LMD-002,Proj Code 157-2
18851 NE 29TH AVE #800 AVENTURA, FL 33180 US		Payment Terms :	30 NET	
· · · · · · · · · · ·				

SUBMIT PAYMENT WITH INVOICE NO. TO: Stanford University PO BOX 884253 LOS ANGELES, CA 90088-4253

PI: Kwo, Paul Y.

Award Title: A Phase 3, Randomized, Open-Label, Parallel Arm Study to Evaluate the Efficacy and Safety of 180 mcg Peginterferon Lambda-1a (Lambda) Subcutaneous Injection for 48 Weeks in Patients with Chronic Hepatitis Delta Virus (HDV) Infection (LIMT-2

Billing Item	Amount
198311: CRF Per Subject	15,998.22
Costs	<14,398.39>
Less: Paid	

CURRENT AMOUNT DUE: \$1,599.83

Please remit "Current Amount Due" with this invoice to prevent further collection efforts. If payment has been made, please disregard this message. Please call (650) 725-0086 or email rfcs-receivables@list.stanford.edu for questions.

I hereby affirm that the above bill is correct and just and that payment thereof has not been received THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY

Natalia

Digitally signed by Natalia Antanavage DN: cn=Natalia Antanavage, o=ORA, ou=SRM

Director of SRM



Subject	Visit Name	Visit Type	Visit Date	Procedure	Completed?	Amount	Balance
9019-2001	Screening for Run-In \$2666.37	Scheduled	09-FEB-2023	Screening for Run-In \$2666.37	Y	\$2,666.37	\$266.64
9019-2002	Screening for Run-In \$2666.37	Scheduled	09-FEB-2023	Screening for Run-In \$2666.37	Y	\$2,666.37	\$266.64
9019-2003	Screening for Run-In \$2666.37	Scheduled	09-FEB-2023	Screening for Run-In \$2666.37	Y	\$2,666.37	\$266.64
9019-2004	Screening for Run-In \$2666.37	Scheduled	09-FEB-2023	Screening for Run-In \$2666.37	Y	\$2,666.37	\$266.64
9019-2005	Screening for Run-In \$2666.37	Scheduled	09-FEB-2023	Screening for Run-In \$2666.37	Y	\$2,666.37	\$266.64
9019-2006	Screening for Run-In \$2666.37	Scheduled	09-FEB-2023	Screening for Run-In \$2666.37	Y	\$2,666.37	\$266.63
Total						\$15,998.22	\$1,599.83

Office of Research Administration

Sponsored Receivables Management

Tax ID Number 94-1156365

INVOICE

	Award	Number:	VAGWT	
то:	Date	05/09/2024	Invoice Number:	58074-2288092-21
EIGER BIOPHARMACEUTICAL			Billing Period:	04/12/24 - 05/09/24
C/O BIORASI LLC			Sponsor Ref No:	EIG-LMD-002,Proj Code 157-2
18851 NE 29TH AVE #800 AVENTURA, FL 33180 US		Payment Terms :	30 NET	
AVENIONA, PH 33100 C				

SUBMIT PAYMENT WITH INVOICE NO. TO: Stanford University PO BOX 884253 LOS ANGELES, CA 90088-4253

PI: Kwo, Paul Y.

Award Title: A Phase 3, Randomized, Open-Label, Parallel Arm Study to Evaluate the Efficacy and Safety of 180 mcg Peginterferon Lambda-1a (Lambda) Subcutaneous Injection for 48 Weeks in Patients with Chronic Hepatitis Delta Virus (HDV) Infection (LIMT-2

Billing Item	Amount
206519: CRF Per Subject	18,314.24
Costs	<16,449.41>
Less: Paid	

CURRENT AMOUNT DUE: \$1,864.83

Please remit "Current Amount Due" with this invoice to prevent further collection efforts. If payment has been made, please disregard this message. Please call (650) 725-0086 or email rfcs-receivables@list.stanford.edu for questions.

I hereby affirm that the above bill is correct and just and that payment thereof has not been received THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY

Natalia

Digitally signed by Natalia Antanavage DN: cn=Natalia Antanavage, o=ORA, ou=SRM

Director of SRM



Subject	Visit Name	Visit Type	Visit Date	Procedure	Completed?	Amount	Balance
9018-2005	PT-1,2013.44, No Pregnancy test \$1976.32	Scheduled	18-OCT-2023	PT-1,2013.44, No Pregnancy test \$1976.32	Y	\$1,976.32	\$197.63
9019-2006	PT-1,2013.44, No Pregnancy test \$1976.32	Scheduled	08-DEC-2023	PT-1,2013.44, No Pregnancy test \$1976.32	Y	\$1,976.32	\$197.63
9018-2005	ST 7, WK 12, Day 85, \$1,816.32	Scheduled	08-AUG-2023	ST 7, WK 12, Day 85, \$1,816.32	Y	\$1,816.32	\$181.63
9018-2005	ST16/EOT, WK48, DAY 337, \$3,246.08	Scheduled	15-SEP-2023	ST16/EOT, WK48, DAY 337, \$3,246.08	Y	\$3,246.08	\$324.61
9019-2006	ST16/EOT, WK48, DAY 337, \$3,246.08	Scheduled	20-SEP-2023	ST16/EOT, WK48, DAY 337, \$3,246.08	Y	\$3,246.08	\$358.02
9018-2005	ST3 \$1,864.96	Scheduled	14-JUN-2023	ST3 \$1,864.96	Y	\$1,864.96	\$186.50
9018-2005	ST4 \$1,239.04	Scheduled	23-JUN-2023	ST4 \$1,239.04	Y	\$1,239.04	\$123.90
9018-2005	ST5 \$1,767.68	Scheduled	23-JUN-2023	ST5 \$1,767.68	Y	\$1,767.68	\$176.77
9018-2005	ST6 \$1,181.44	Scheduled	25-JUL-2023	ST6 \$1,181.44	Y	\$1,181.44	\$118.14
Total						\$18,314.24	\$1,864.83

Office of Research Administration Sponsored Receivables Management

Tax ID Number 94-1156365

INVOICE

	Award	Number:	VAGWT	
то:	Date	05/16/2024	Invoice Number:	58074-2288385-22
EIGER BIOPHARMACEUTICAL			Billing Period:	05/10/24 - 05/16/24
C/O BIORASI LLC 18851 NE 29TH AVE #800 AVENTURA, FL 33180 US		Sponsor Ref No:	EIG-LMD-002,Proj Code 157-2	
		Payment Terms :	30 NET	

SUBMIT PAYMENT WITH INVOICE NO. TO: Stanford University PO BOX 884253 LOS ANGELES, CA 90088-4253

PI: Kwo, Paul Y.


Award Title: A Phase 3, Randomized, Open-Label, Parallel Arm Study to Evaluate the Efficacy and Safety of 180 mcg Peginterferon Lambda-1a (Lambda) Subcutaneous Injection for 48 Weeks in Patients with Chronic Hepatitis Delta Virus (HDV) Infection (LIMT-2

Billing	Item	Amount
206796:	Per Subject Costs	6,082.56

CURRENT AMOUNT DUE: \$6,082.56

Please remit "Current Amount Due" with this invoice to prevent further collection efforts. If payment has been made, please disregard this message. Please call (650) 725-0086 or email rfcs-receivables@list.stanford.edu for questions.

I hereby affirm that the above bill is correct and just and that payment thereof has not been received THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY



Digitally ugned by Natalia Antanavage DN: cn=Natalia Antanavage, o=ORA, ou=SRM

Director of SRM



Subject	Visit Name	Visit Type	Visit Date	Procedure	Completed?	Amount	Balance
9019-2001	ARM 2: ST 16/EOT, WK60, DAY 421, \$3,041.28	Scheduled	13-SEP-2023	ARM 2: ST 16/EOT, WK60, DAY 421, \$3,041.28	Y	\$3,041.28	\$3,041.28
9019-2005	ARM 2: ST 16/EOT, WK60, DAY 421, \$3,041.28	Scheduled	18-SEP-2023	ARM 2: ST 16/EOT, WK60, DAY 421, \$3,041.28	Y	\$3,041.28	\$3,041.28
Total						\$6,082.56	\$6,082.56

Office of Research Administration

Sponsored Receivables Management Tax ID Number 94-1156365

INVOICE

Award Number:VAGWTTO:Date05/28/2024Invoice Number:58074-2290144-23EIGER BIOPHARMACEUTICALBilling Period:05/17/24 - 05/28/24C/O BIORASI LLCSponsor Ref No:EIG-LMD-002,Proj Code 157-218851 NE 29TH AVE #800
AVENTURA, FL 33180 USPayment Terms :30 NET

SUBMIT PAYMENT WITH INVOICE NO. TO: Stanford University PO BOX 884253 LOS ANGELES, CA 90088-4253

PI: Kwo, Paul Y.

Award Title: A Phase 3, Randomized, Open-Label, Parallel Arm Study to Evaluate the Efficacy and Safety of 180 mcg Peginterferon Lambda-1a (Lambda) Subcutaneous Injection for 48 Weeks in Patients with Chronic Hepatitis Delta Virus (HDV) Infection (LIMT-2

Billing I	tem	Amount
207143:	Other Study Related	1,920.00
Fees		

CURRENT AMOUNT DUE: \$1,920.00

Please remit "Current Amount Due" with this invoice to prevent further collection efforts. If payment has been made, please disregard this message. Please call (650) 725-0086 or email rfcs-receivables@list.stanford.edu for questions.

I hereby affirm that the above bill is correct and just and that payment thereof has not been received THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY

Natalia

Digitally signed by Natalia Antanavage DN: cn=Natalia Antanavage, o=ORA, ou=SRM

Antanavage Director of SRM



Fee	Date	Amount
Pharmacy Annual Maintenance Fee \$1,920.00, 2/9/2023 (period 2023-2024)	09-FEB-2023	\$1,920.00
Total		\$1,920.00

Office of Research Administration Sponsored Receivables Management

Tax ID Number 94-1156365

INVOICE

	Award	Number:	VAGWT	
то:	Date	11/30/2023	Invoice Number:	58074-2258248-9
EIGER BIOPHARMACEUTICAL		Billing Period:	11/22/23 - 11/30/23	
C/O BIORASI LLC 18851 NE 29TH AVE #800 AVENTURA, FL 33180 US		Sponsor Ref No:	EIG-LMD-002,Proj Code 157-2	
		Payment Terms :	30 NET	
AVENTURA, FL 33180	US			SO NET

SUBMIT PAYMENT WITH INVOICE NO. TO: Stanford University PO BOX 884253 LOS ANGELES, CA 90088-4253

PI: Kwo, Paul Y.

Award Title: A Phase 3, Randomized, Open-Label, Parallel Arm Study to Evaluate the Efficacy and Safety of 180 mcg Peginterferon Lambda-1a (Lambda) Subcutaneous Injection for 48 Weeks in Patients with Chronic Hepatitis Delta Virus (HDV) Infection (LIMT-2

Billing Item	Amount
201779: CRF Per Subject	32,616.46
Costs	<29,354.80>
Less: Paid	

CURRENT AMOUNT DUE: \$3,261.66

Please remit "Current Amount Due" with this invoice to prevent further collection efforts. If payment has been made, please disregard this message. Please call (650) 725-0086 or email rfcs-receivables@list.stanford.edu for questions.

I hereby affirm that the above bill is correct and just and that payment thereof has not been received THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY

Natalia

Digitally signed by Natalia Antanavage DN: cn=Natalia Antanavage, o=ORA, ou=SRM

Antanavage

Director of SRM



Subject	Visit Name	Visit Type	Visit Date	Procedure	Completed?	Amount	Balance
9019-2005	NT 1 \$1021.44	Scheduled	07-JUL-2023	NT 1 \$1021.44	Y	\$1,021.44	\$102.14
9019-2001	NT 1 \$1021.44	Scheduled	21-JUL-2023	NT 1 \$1021.44	Y	\$1,021.44	\$102.14
9019-2005	NT 2: \$674.56	Scheduled	14-JUL-2023	NT 2: \$674.56	Y	\$674.56	\$67.46
9019-2001	NT 2: \$674.56	Scheduled	27-JUL-2023	NT 2: \$674.56	Y	\$674.56	\$67.46
9019-2005	NT 3 \$1,021.44	Scheduled	26-JUL-2023	NT 3 \$1,021.44	Y	\$1,021.44	\$102.14
9019-2001	NT 3 \$1,021.44	Scheduled	09-AUG-2023	NT 3 \$1,021.44	Y	\$1,021.44	\$102.14
9019-2005	NT 4, \$648.96	Scheduled	10-AUG-2023	NT 4, \$648.96	Y	\$648.96	\$64.90
9019-2001	NT 4, \$648.96	Scheduled	25-AUG-2023	NT 4, \$648.96	Y	\$648.96	\$64.90
9019-2005	NT 5 \$1,021.44	Scheduled	23-AUG-2023	NT 5 \$1,021.44	Y	\$1,021.44	\$102.14
9019-2005	NT 6, \$648.96	Scheduled	06-SEP-2023	NT 6, \$648.96	Y	\$648.96	\$64.90
9019-2005	Randomization \$1594.88	Scheduled	28-JUN-2023	Randomization \$1594.88	Y	\$1,594.88	\$159.49
9019-2001	Randomization \$1594.88	Scheduled	12-JUL-2023	Randomization \$1594.88	Y	\$1,594.88	\$159.49
9019-2006	Randomization/BL \$3558.40	Scheduled	28-JUN-2023	Randomization/BL \$3558.40	Y	\$3,558.40	\$355.84
9019-2006	ST1 \$1,601.28	Scheduled	07-JUL-2023	ST1 \$1,601.28	Y	\$1,601.28	\$160.13
9019-2006	ST2 \$1,305.60	Scheduled	17-JUL-2023	ST2 \$1,305.60	Y	\$1,305.60	\$130.56
9019-2006	ST3 \$1,827.84	Scheduled	26-JUL-2023	ST3 \$1,827.84	Y	\$1,827.84	\$182.78
9019-2006	ST4 \$1,239.04	Scheduled	10-AUG-2023	ST4 \$1,239.04	Y	\$1,239.04	\$123.90
9019-2006	ST5 \$1,730.56	Scheduled	23-AUG-2023	ST5 \$1,730.56	Y	\$1,730.56	\$173.06
9019-2006	ST6 \$1,181.44	Scheduled	08-SEP-2023	ST6 \$1,181.44	Y	\$1,181.44	\$118.14
9019-2003	Screening for Eligibility - \$2,859.78	Scheduled	19-MAY-2023	Screening for Eligibility - \$2,859.78	Y	\$2,859.78	\$285.98
9019-2004	Screening for Eligibility - \$2,859.78	Scheduled	26-MAY-2023	Screening for Eligibility - \$2,859.78	Y	\$2,859.78	\$285.98
9019-2006	Screening for Eligibility - \$2,859.78	Scheduled	26-MAY-2023	Screening for Eligibility - \$2,859.78	Y	\$2,859.78	\$285.99
Total						\$32,616.46	\$3,261.66

Office of Research Administration Sponsored Receivables Management

Tax ID Number 94-1156365

INVOICE

	Award	Number:	VAGWT		
то:	Date	09/18/2023	Invoice Number:	58074-2245833-5	
EIGER BIOPHARMACEUT	ICAL		Billing Period:	09/15/23 - 09/18/23	
C/O BIORASI LLC			Sponsor Ref No:	EIG-LMD-002,Proj Code 157-2	
18851 NE 29TH AVE #800 AVENTURA, FL 33180 US			Payment Terms :	30 NET	
AVENIONA, IL 55100 (50				

SUBMIT PAYMENT WITH INVOICE NO. TO: Stanford University PO BOX 884253 LOS ANGELES, CA 90088-4253

PI: Kwo, Paul Y.

Award Title: A Phase 3, Randomized, Open-Label, Parallel Arm Study to Evaluate the Efficacy and Safety of 180 mcg Peginterferon Lambda-1a (Lambda) Subcutaneous Injection for 48 Weeks in Patients with Chronic Hepatitis Delta Virus (HDV) Infection (LIMT-2

Billing Item	Amount
199683: CRF Per Subject	5,719.56
Costs	<5,147.60>
Less: Paid	

CURRENT AMOUNT DUE:

\$571.96

Please remit "Current Amount Due" with this invoice to prevent further collection efforts. If payment has been made, please disregard this message. Please call (650) 725-0086 or email rfcs-receivables@list.stanford.edu for questions.

I hereby affirm that the above bill is correct and just and that payment thereof has not been received THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY

Natalia

Digitally signed by Natalia Antanavage DN: cn=Natalia Antanavage, o=ORA, ou=SRM

Antanavage



Director of SRM

Subject	Visit Name	Visit Type	Visit Date	Procedure	Completed?	Amount	Balance
9019-2001	Screening for Eligibility - \$2,859.78	Scheduled	19-MAY-2023	Screening for Eligibility - \$2,859.78	Y	\$2,859.78	\$285.98
9019-2005	Screening for Eligibility - \$2,859.78	Scheduled	26-MAY-2023	Screening for Eligibility - \$2,859.78	Y	\$2,859.78	\$285.98
Total						\$5,719.56	\$571.96